- Home
- CTOS vs NRIX Comparison
CTOS vs NRIX Comparison
Compare CTOS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- NRIX
- Stock Information
- Founded
- CTOS 1988
- NRIX 2009
- Country
- CTOS United States
- NRIX United States
- Employees
- CTOS N/A
- NRIX N/A
- Industry
- CTOS Diversified Commercial Services
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- CTOS Consumer Discretionary
- NRIX Health Care
- Exchange
- CTOS Nasdaq
- NRIX Nasdaq
- Market Cap
- CTOS 1.1B
- NRIX 952.9M
- IPO Year
- CTOS N/A
- NRIX 2020
- Fundamental
- Price
- CTOS $4.76
- NRIX $11.49
- Analyst Decision
- CTOS Hold
- NRIX Strong Buy
- Analyst Count
- CTOS 3
- NRIX 16
- Target Price
- CTOS $5.33
- NRIX $30.44
- AVG Volume (30 Days)
- CTOS 359.5K
- NRIX 796.7K
- Earning Date
- CTOS 07-31-2025
- NRIX 07-10-2025
- Dividend Yield
- CTOS N/A
- NRIX N/A
- EPS Growth
- CTOS N/A
- NRIX N/A
- EPS
- CTOS N/A
- NRIX N/A
- Revenue
- CTOS $1,813,205,000.00
- NRIX $56,417,000.00
- Revenue This Year
- CTOS $11.08
- NRIX $16.69
- Revenue Next Year
- CTOS $5.69
- NRIX N/A
- P/E Ratio
- CTOS N/A
- NRIX N/A
- Revenue Growth
- CTOS N/A
- NRIX N/A
- 52 Week Low
- CTOS $3.03
- NRIX $8.18
- 52 Week High
- CTOS $6.11
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- CTOS 60.17
- NRIX 50.78
- Support Level
- CTOS $4.65
- NRIX $12.25
- Resistance Level
- CTOS $4.86
- NRIX $12.00
- Average True Range (ATR)
- CTOS 0.15
- NRIX 0.69
- MACD
- CTOS 0.01
- NRIX -0.08
- Stochastic Oscillator
- CTOS 84.96
- NRIX 21.57
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.